Advice
Following a full submission
adalimumab (Humira®) is not recommended for use within NHS Scotland for the treatment of severe, active Crohn’s disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
In both induction and maintenance studies in patients with severe active Crohn’s disease, more patients treated with adalimumab achieved and maintained clinical remission than with placebo. However, the manufacturer did not present a sufficiently robust economic case to gain acceptance by the SMC.
Download detailed advice99KB (PDF)
Medicine details
- Medicine name:
- adalimumab 40mg solution for injection (Humira)
- SMC ID:
- 417/07
- Indication:
- Severe active crohn' s disease
- Pharmaceutical company
- Abbott Laboratories
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 12 November 2007